New drug may shield kidneys in liver cirrhosis patients
NCT ID NCT07585526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if the drug finerenone can prevent chronic kidney disease in adults with liver cirrhosis caused by fatty liver disease (MASLD) who also have fluid buildup in the belly (ascites). About 160 participants will receive either finerenone or spironolactone, along with standard care, for 6 months. The main goal is to see which drug better protects kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new graft keep dialysis access working longer?
- Can a common gout pill shield hearts in kidney disease?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Hidden liver risk in type 1 diabetes: a new study investigates